HRT for Women Over 40: What to Know | PeptideWorld

HRT for Women Over 40: What to Know

🧬 Hormone Health ⏱ 13 min read 🎓 Beginner – Intermediate
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. HRT is a prescription treatment that requires individual risk-benefit assessment with a licensed physician, ideally one specialised in menopause medicine.

For most women, the hormonal changes of midlife begin in the 40s — sometimes the early 40s, occasionally the late 30s — long before menopause itself. The decade between first perimenopausal symptoms and post-menopause is often the most symptomatic, the least well-managed, and the most confusing to navigate. Women in their 40s are frequently told their symptoms are "too early" for menopause, given inadequate testing, and sent away without treatment.

This guide is specifically for women in their 40s and early 50s — where the clinical picture looks different from established menopause, where the evidence for HRT is most clearly favourable, and where the most common mistakes in medical management occur.

Key Takeaways

  • Perimenopause — the hormonal transition to menopause — typically begins in the mid-40s, but can start in the late 30s. Symptoms of hormonal change in this decade are not "too early" to evaluate or treat.
  • The NAMS 2022 Position Statement — endorsed by 20+ international organisations — explicitly states that for women under 60 or within 10 years of menopause with no contraindications, the benefits of HRT outweigh the risks.
  • NAMS moved away from "lowest dose for shortest time" to "appropriate dose, duration, regimen, and route" — recognising that undertreating menopause has its own harms.
  • FSH blood tests are unreliable for diagnosing perimenopause because hormone levels fluctuate dramatically. NICE 2024 guidelines recommend diagnosis based on symptoms in women over 40, not on blood tests alone.
  • A 2024 Menopause Society study (Medicare data) found that estrogen monotherapy beyond age 65 was associated with risk reductions in mortality, breast cancer, heart attack, and dementia — challenging the assumption that HRT must stop at 65.
  • Testosterone supplementation for women — low-dose transdermal — is a legitimate and evidence-backed treatment for low libido and energy in menopausal women, though widely under-prescribed.

The Hormonal Transition: Stages That Matter for Treatment

The Menopausal Transition — What Changes When

Late 30s–early 40s
Progesterone often declines first — before estrogen and before menstrual irregularity. Symptoms: sleep disruption, increased anxiety, PMS intensification, mood changes. Often misdiagnosed as anxiety disorder. FSH often normal. Estradiol may still cycle normally.
Mid-40s
Early perimenopause — estrogen levels begin fluctuating erratically (often high then crashing, not simply declining). These fluctuations produce more intense symptoms than stable low estrogen. Hot flashes begin. Menstrual cycles may shorten or lengthen. Contraception is still needed — ovulation continues unpredictably.
Late 40s–early 50s
Late perimenopause — menstrual cycles become irregular (more than 60 days between periods). Vasomotor symptoms (hot flashes, night sweats) often most severe in this phase. Estrogen variability is at its greatest — estrogen withdrawal between cycles can be more symptomatic than steady low estrogen. FSH begins to rise consistently.
Average age 51–52
Menopause — defined as 12 consecutive months without a period. Estrogen settles at a stable low level. FSH remains consistently elevated. Most vasomotor symptoms begin to improve in the first few years post-menopause for some women, but genitourinary symptoms (vaginal atrophy, urinary changes) often worsen progressively.
Post-menopause
Ongoing estrogen deficiency effects — accelerated bone loss (up to 20% in first 5 years), cardiovascular risk changes, continued genitourinary progression, possible cognitive vulnerability. HRT within the timing window (under 60 or within 10 years of menopause) has its most clearly favourable benefit-risk profile here.

The Diagnosis Problem in the 40s

Why Blood Tests Don't Diagnose Perimenopause — and Why This Matters

One of the most frequent clinical errors women in their 40s encounter is being told "your hormone levels are normal" and being sent away without treatment despite clearly experiencing symptoms of hormonal transition. The reason this happens: FSH, the pituitary hormone most commonly tested, is unreliable in perimenopause.

During perimenopause, estrogen — and therefore FSH — fluctuates dramatically from week to week and even day to day. A normal FSH on a Tuesday says nothing about what FSH was on the previous Saturday. A woman can have a severely symptomatic perimenopausal presentation with a completely normal FSH on the day of testing.

The NICE 2024 guideline position: Diagnose perimenopause in women over 40 based on symptoms — including irregular periods, vasomotor symptoms, sleep disruption, and mood changes — without requiring blood tests to confirm. This reflects the reality that symptoms, not hormone levels, determine whether treatment is appropriate. Hormonal testing has a place (particularly to rule out other causes and in women under 45), but it should not be a gateway that prevents treatment in symptomatic women.

Common Perimenopausal Symptoms in the 40s

The symptom profile of perimenopause in the 40s often differs from what most women expect — partly because vasomotor symptoms (hot flashes) are not always prominent in early perimenopause. The earliest symptoms are often sleep-related, mood-related, or cognitive.

Sleep Disruption Often the first symptom — progesterone's role in sleep is disrupted before estrogen declines significantly. Night waking, difficulty getting back to sleep, and non-restorative sleep are common.
Anxiety and Mood Changes New-onset anxiety or worsening existing anxiety in the late 30s and 40s is frequently hormonal. Estrogen modulates serotonin, dopamine, and GABA — its fluctuation disrupts mood regulation.
Brain Fog Word-finding difficulties, short-term memory lapses, difficulty concentrating. Often misattributed to stress or aging. Estrogen supports neurological function and cerebral blood flow — its decline affects cognition.
Menstrual Changes Cycles may shorten (follicular phase shortens first), become heavier, or less predictable. Any change in long-established cycle pattern in the 40s warrants perimenopausal evaluation.
Hot Flashes / Night Sweats May begin in the mid-40s but often become more prominent in late perimenopause. The severity of estrogen withdrawal between cycles (not low estrogen per se) drives this symptom — making perimenopause sometimes more symptomatic than established menopause.
Reduced Libido Affects both estrogen and testosterone pathways. Progressive through the menopausal transition. Often the symptom women are most reluctant to discuss but that most significantly affects quality of life.
Joint Pain and Muscle Changes Estrogen has anti-inflammatory properties in joints. Its decline contributes to new-onset musculoskeletal aches, reduced muscle recovery, and joint stiffness — often dismissed as "just getting older."
Cardiovascular Symptoms Heart palpitations are common in perimenopause — often linked to estrogen fluctuations affecting cardiac rhythm. Typically benign but warrant investigation to rule out arrhythmia.

What the Current Evidence and Guidelines Say

The Menopause Society (formerly NAMS) 2022 Position Statement — Key Clinical Points

The most authoritative evidence-based guidance on HRT for women in the menopausal transition, endorsed by over 20 international medical organisations:

  • HRT is the most effective treatment for vasomotor symptoms — no non-hormonal treatment approaches its efficacy for moderate to severe hot flashes and night sweats
  • For women under 60 or within 10 years of menopause with no contraindications: benefits outweigh risks — this is the clearest clinical guidance available
  • The previous guidance of "lowest dose for shortest time" has been replaced with "appropriate dose, duration, regimen, and route" — acknowledging that undertreating menopause carries its own harms
  • Risk stratification by age and time since menopause is recommended — not blanket caution regardless of individual circumstances
  • Duration of use should be "an individual decision" between patient and physician — not automatically limited to 5 years

Source: NAMS 2022 Hormone Therapy Position Statement (Menopause journal). The Menopause Society reaffirmed this guidance in its updated position papers.[1]

Who Should and Should Not Use HRT: The Decision Framework

✓ Generally Appropriate

Women under 60 or within 10 years of menopause with bothersome vasomotor or genitourinary symptoms and no contraindications. Symptomatic perimenopause of any age over 40 where symptoms affect quality of life. Early menopause (before 45) — HRT recommended until at least average menopause age.

⚠️ Requires Individual Assessment

Women over 60 or more than 10 years post-menopause (benefits still possible with appropriate formulation and monitoring). Women with cardiovascular risk factors (transdermal preferred). Those with higher breast cancer risk. History of VTE with transdermal estrogen as first choice.

🔴 Requires Specialist Input

Active or recent hormone-receptor-positive breast cancer. Uncontrolled cardiovascular disease. Unexplained vaginal bleeding. Active liver disease. Thrombogenic mutations. History of VTE — not an absolute contraindication with transdermal, but specialist guidance required.

The Contraception Complication in the 40s

One of the most clinically important issues for women in their 40s: contraception and HRT are not the same thing, and hormonal contraceptives do not replace HRT — and vice versa. Women in perimenopause remain at risk of unintended pregnancy until they have been amenorrhoeic for 12 months (or 24 months if under 50). Standard HRT does not provide contraception.

The most practical solution for perimenopausal women who need both: the levonorgestrel-releasing intrauterine system (Mirena IUS) provides endometrial protection for the estrogen in HRT and simultaneously provides highly effective contraception. This allows transdermal estradiol to be used for symptom management while the IUS protects both the uterus and fertility control. Low-dose combined oral contraceptives are an alternative, particularly for women with irregular bleeding who want cycle control, but contain higher dose hormones than standard HRT.[2]

Formulation Choices: Getting the Details Right

Transdermal Estradiol (Preferred Route) Patches (applied 1–2× per week), gels (applied daily), or sprays. Bypasses liver metabolism — eliminates VTE risk associated with oral estrogen. Preferred for women with cardiovascular risk factors, VTE history, migraines with aura, and for most perimenopausal women as standard of care under current guidance. Estradiol (E2) — the bioidentical form — is the most commonly prescribed.
Oral Estrogen (Tablets) Convenient once-daily dosing. Effective for symptom management. Undergoes first-pass liver metabolism — increases clotting factor production, modestly raises VTE risk, increases SHBG (which reduces free testosterone). Still widely used where transdermal is not tolerated or preferred, but less favoured in women with additional risk factors.
Micronised Progesterone (Preferred Progestogen) Utrogestan or Prometrium — bioidentical progesterone. Evidence suggests lower associated breast cancer risk than synthetic progestins. Also improves sleep (GABA modulation) — taken at bedtime produces a beneficial sedating effect. UK and European guidelines increasingly favour micronised progesterone over synthetic progestins. Oral or vaginal route.
Mirena IUS (Levonorgestrel IUD) Delivers progestogen locally to the uterus with minimal systemic absorption. Provides endometrial protection for transdermal estrogen. Also provides contraception — making it particularly suitable for perimenopausal women. Does not produce the systemic progestogen side effects of oral progestins. Effective for 5 years.
Local (Vaginal) Estrogen Cream, ring, tablet, or gel applied vaginally. Minimal systemic absorption. First-line for genitourinary symptoms (vaginal dryness, urinary frequency, recurrent UTIs). Can be used at any age, including in women with contraindications to systemic HRT. Does not require progestogen even in women with a uterus. Appropriate for long-term use.
Continuous vs Sequential Regimens Sequential: estrogen daily, progestogen for 12–14 days per month — produces a monthly withdrawal bleed. Used in perimenopause/early menopause. Continuous combined: both hormones daily, no bleed — suitable for women who are at least 12 months post-menopause. Many women prefer the convenience of continuous combined once eligible.

Testosterone for Women: The Under-Recognised Piece

What Most Clinicians Don't Discuss

Testosterone is not just a male hormone. Women produce testosterone in the ovaries and adrenal glands, and it plays a meaningful role in libido, energy, mood, cognitive sharpness, and muscle maintenance. Testosterone declines significantly through the menopausal transition — and in women on oral estrogen, the decline is worsened because oral estrogen raises SHBG, which further reduces free testosterone.

The evidence for testosterone in women: The Menopause Society and British Menopause Society both endorse low-dose transdermal testosterone as evidence-based treatment for hypoactive sexual desire disorder (HSDD) in menopausal women. A 2025 Cochrane review confirmed testosterone therapy improves sexual function in women. The dose is approximately one-tenth of what men receive.

The practical issue: No testosterone product is licensed specifically for women in most countries, including the US. Testosterone is used off-label via compounded cream or gel at female-appropriate doses. Many physicians are not trained in this application and do not offer it. Women who feel that their libido, energy, or mental sharpness remains inadequate despite appropriate estrogen and progesterone therapy should specifically ask about testosterone assessment (free testosterone and SHBG).

Oral estrogen and free testosterone: If a woman on oral estrogen has low libido, switching to transdermal estrogen reduces SHBG and can improve free testosterone without adding any new medication — this is worth trying before adding testosterone separately.

The Age 65+ Question: Do You Have to Stop?

📊 2024 Menopause Society Study: Continuing HRT Beyond 65 May Be Beneficial A large 2024 study published in Menopause (The Menopause Society's journal) examined Medicare data from women using HRT beyond age 65. The findings challenged the long-held assumption that HRT must stop at 65: estrogen monotherapy beyond 65 was associated with significant risk reductions in all-cause mortality, breast cancer, lung cancer, colorectal cancer, congestive heart failure, VTE, atrial fibrillation, heart attack, and dementia. Combined estrogen + progestogen beyond 65 did show increased breast cancer risk — but this could be mitigated by using low-dose transdermal estrogen with a progestin at appropriate doses. The researchers concluded that women "may be able to safely continue hormone therapy beyond age 65" with appropriate monitoring and individualised decision-making.[3]

Five Common Myths — Corrected

MYTH
"Your symptoms are too early for perimenopause — you're only 43."
FACT
Perimenopause typically begins in the mid-40s but can start in the late 30s. Progesterone often declines before estrogen, producing symptoms years before menstrual irregularity begins. NICE 2024 guideline: diagnose based on symptoms over 40, not age.
MYTH
"Your FSH is normal so you're not in perimenopause."
FACT
FSH fluctuates dramatically in perimenopause — a single normal reading does not exclude it. NICE 2024: do not rely on FSH alone to diagnose or exclude perimenopause in symptomatic women over 40.
MYTH
"You should only take HRT for 5 years maximum."
FACT
NAMS explicitly moved away from the "lowest dose for shortest time" position. Duration is an individualised decision. Many women have ongoing symptoms and quality-of-life needs that make longer-term use appropriate under clinical supervision.
MYTH
"All HRT is the same — it all carries the same risks."
FACT
Route, type, and dose all materially affect risk. Transdermal estrogen does not carry oral estrogen's VTE risk. Micronised progesterone has a different (likely lower) breast cancer risk profile than synthetic MPA. Formulation choice is clinically significant.
MYTH
"HRT must stop at age 65."
FACT
A 2024 Menopause Society study found estrogen monotherapy beyond 65 was associated with reduced mortality and multiple health benefits. The decision to continue or stop HRT beyond 65 should be made individually, not automatically. NAMS: "Women do not need to stop taking HRT at 65."

The Single Most Important Message

The goal of modern menopause medicine is not risk avoidance — it is individualised risk-benefit assessment. Untreated perimenopause and menopause carry their own risks: accelerated bone loss, cardiovascular changes, cognitive vulnerability, and years of poor quality of life. For most women in their 40s and early 50s who are appropriate candidates, the weight of current evidence supports HRT as a safe and effective treatment — and the evidence base for that position has never been stronger than it is today.

Want to understand your HRT options before speaking with a clinician?

Our free quiz helps you think through your situation clearly.

Take Our Peptide Plan Quiz →

References

  1. The Menopause Society (NAMS). 2022 Hormone Therapy Position Statement. Menopause journal. Endorsed by 20+ international organisations. Available from: https://menopause.org
  2. PMC. The 2025 Menopausal Hormone Therapy Guidelines — Korean Society of Menopause. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12438153/
  3. The Menopause Society. Women aged older than 65 years may be able to safely continue taking hormone therapy. Press release, April 2024. Available from: https://menopause.org
  4. NICE 2024. Menopause: Identification and Management Guideline. Summary via Medscape. Available from: https://reference.medscape.com
  5. PMC. Menopausal Hormone Therapy — Risks, Benefits and Emerging Options: A Narrative Review. Nov 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12652300/
  6. The ObG Project. The Menopause Society: Hormone Therapy Statement — November 2025 FDA Update. Available from: https://www.obgproject.com
  7. Breast Cancer.org. North American Menopause Society Updates Position Statement on Hormone Therapy. 2022. Available from: https://www.breastcancer.org